Aquila’s vision is to evolve with innovation at the core, as global leaders in contract research, enhancing drug discovery programmes using cutting-edge research, facilitating the development of new medicines for the benefit of human health.
Encompassed within our vision is the need to continually develop novel high impact clinically relevant models in line with our client’s requirements. This is either at our instigation or client-led.
For client led projects, Aquila will discuss individual project needs, validating new methods and assays to deliver on agreed objectives. Flexibility and creativity are key to success. Aquila is committed to developing strong working relationships with our clients, and using open innovation to build new and potentially more clinically relevant models using GLP-like standards of quality we have the capacity to offer biology-led solutions.
Aquila is currently building on its Immuno-Oncology capabilities, particularly around offering models utilising human patient materials, ovarian tumour ascites and fresh human tumour samples (Human Tumour Ex-vivo Systems). These assays will offer an opportunity to generate high value mechanistic ‘human’ data on novel immunomodulators prior to progression into in-vivo tumour models or clinical trials.
Please contact us if you have an interest in projects currently in development for a status update or if you have any other projects that you would like us to consider developing.